Vial Announces the Addition of Dr. Marc Hoffmann from the University of Kansas Medical Center to their Oncology CRO Scientific Advisory Board

Vial, a tech-enabled CRO providing next-generation clinical trial management services, announced the addition of Marc Hoffmann, MD, to Vial’s Scientific Advisory Board. Dr. Hoffmann will work closely with the company’s leadership team to shape the scientific strategy of Vial’s Oncology CRO products and services.

“Vial’s vision is to empower scientists to cure all human disease. We are elated to see our vision endorsed by such an esteemed leader in oncology. Undoubtedly, Dr. Hoffmann will be an invaluable resource as we advance our Oncology CRO and technology platform,” said Richard McCormick Jr., VP of Oncology at Vial.

Vial promises to deliver faster, more efficient trials for biotech sponsors at up to 50% less cost. The Vial Oncology CRO distinguishes itself by leveraging digital technology, such as its Vial Technology Platform, combining eSource, EDC, eTMF, and ePRO into one connected system to streamline site processes. These best-in-class CRO services will accelerate the development of new therapies and devices for oncology sponsors and patients.

“I am excited to provide guidance to the Vial team as they progress their Oncology CRO and technology platform. Vial is committed to empowering oncology research teams to discover new therapies for patients with cancer through more efficient clinical trial processes. I am eager to see their progress as they continue their product development,” said Marc Hoffmann.

Dr. Hoffman is the Medical Director for Lean and Quality Improvement in the Cancer Center, Chair of the Lymphoma/Myeloma Disease Working Group, and an associate professor at the University of Kansas.